Назаретский Крест |
|
Русский Text
|
| Thrombotech to begin Phase I trial of stroke treatment |
| 05/02/2010 |
| Hadasit Bio Holdings Ltd. (TASE:HDST) portfolio company Thrombotech Technologies Ltd. has obtained Ministry of Health approval to begin a Phase I human clinical trial of its stroke treatment, a peptide, THR-18, which is administered alongside existing stroke treatments.
The trial will include 40 healthy volunteers to test the safety of THR-18 to enable its possible use for a range of indications, including heart attacks, traumatic brain injury, lung embolisms, and blocked arteries and veins in the legs and arms. The trial is scheduled to begin later at Hadassah Medical Center in Ein Kerem, Jerusalem, in the first quarter of 2010.
|
|
|
|
|
|
;void(0);){kind=link}
